Aspen Neuroscience, Inc.
ASPE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002124080
In the last 90 days, Aspen Neuroscience, Inc. insiders filed 3 open-market purchases and 0 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Key figures
- Market capNo recent share count in SEC filings
- –
- Insider buysLast 90 days, $35.0M in total
- 3
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026
- 0
- 13F valueReported value at the end of Q2 2026
- $0
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ASPE, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding ASPE at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Aspen Neuroscience, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 4, 2026 (view filing)6:47 PM ET | Nov 2 | 2 days | Thompson Peter A.Director, 10% Owner | PPurchase | +1.00M | $15.00 | +$15.0M | +38.6%3.59M after | Duplicate filing |
| Nov 4, 2026 (view filing)6:43 PM ET | Nov 2 | 2 days | OrbiMed Advisors LLC and 1 otherDirector, 10% Owner | PPurchase | +1.00M | $15.00 | +$15.0M | +38.6%3.59M after | |
| Nov 2, 2026 (view filing)9:50 PM ET | Nov 2 | Same day | Crandell Keith and 8 others10% Owner | PPurchase | +133.3K | $15.00 | +$2.00M | New position66.7K after | 2 lots |
| Nov 2, 2026 (view filing)9:50 PM ET | Nov 2 | Same day | Crandell Keith and 8 others10% Owner | PPurchase | +1.20M | $15.00 | +$18.0M | New position1.20M after | Duplicate filing |
| Nov 2, 2026 (view filing)9:46 PM ET | Nov 2 | Same day | Berns Paul L and 3 others10% Owner | PPurchase | +1.20M | $15.00 | +$18.0M | New position1.20M after |
Top 10 13F holders, Q2 2026
View all: Top 10 13F holders, Q2 2026The largest institutional positions in Aspen Neuroscience, Inc. at the end of Q2 2026; share changes are against Q1 2026.
No institution reported holding ASPE in 13F filings for Q2 2026.
Holders of 5% or more of ASPE
See all 6 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Aspen Neuroscience, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| ARCH Venture Fund X, L.P. | 13D | 12.90%3.75M shares | New | Nov 9, 20261 filing | Nov 9, 2026 | SEC |
| OrbiMed Advisors LLC | 13D | 12.30%3.59M shares | New | Nov 6, 20261 filing | Nov 6, 2026 | SEC |
| FMR LLC | 13G | 11.20%3.25M shares | New | Nov 6, 20261 filing | Nov 6, 2026 | SEC |
| Gilead Sciences, Inc. | 13G | 9.90%2.88M shares | New | Nov 6, 20261 filing | Nov 6, 2026 | SEC |
| Qatar Investment Authority | 13G | 6.70%1.93M shares | New | Nov 3, 20261 filing | Nov 3, 2026 | SEC |